Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Aug 11;31(3):178–188. doi: 10.1038/jhh.2016.54

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Macmillan Publishers Limited, part of Springer Nature.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Incidence rate of oedema during 8 weeks of treatment with nifedipine GITS (N20, 30, 60) and/or candesartan cilexetil (C4, 8, 16, 32) in individuals with (a) renal impairment (baseline eGFR<90 ml min⁻¹), (b) T2DM, (c) hypercholesterolaemia (total cholesterol>240 mg dl⁻¹) or (d) any CV risk factors (T2DM or BMI⩾30 kg m⁻² or LDL⩾130 mg dl⁻¹). Abbreviations: BMI, body mass index; C, candesartan cilexetil; CV, cardiovascular; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; N, nifedipine GITS; T2DM, type 2 diabetes mellitus.